An observational study in Dyslipidemias, Lipid Testing and Myocardial Infarction, sponsored by Montreal Heart Institute. Recruiting at 2 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-03.
Sponsored by Montreal Heart Institute · Observational
Because treatment decisions are usually based on a single measurement of the lipid panel at the time of an admission for an MI, the overarching objective of this project is to evaluate whether the measurement of LDL, non-HDL, and apoB values are reliable through all the duration of the hospitalization.
It will be a single-center, prospective, observational study will be conducted, including consecutive patients hospitalized for myocardial infarction at the Montreal Heart Institute.
Every patient at the Cardiac Care Unit will undergo non-fasting lipid panel testing at day 0 of their admission for Myocardial Infarction during the study period. Patients who consent to participate will have a 2nd non-fasting lipid panel drawn at day 2 of their admission.
Thereafter, the levels of the different lipid values from the panel will be compared between day 0, day 2, and 4-6 weeks after discharge.
We hypothesize that LDL, non-HDL, and apoB values are highest at time of admission and more reflective of the true patient's values, and lower near the time of discharge. Therefore, the timing of testing for the lipid panel during an admission for MI can impact the intensity with which dyslipidemia is treated (i.e. intensity of pharmacologic therapy at discharge), and followed (timing of subsequent lipid panel testing).
The objective of this project is to evaluate whether the measurement of LDL, non-HDL, and apoB values are reliable through all the duration of the hospitalization, from day 0 to day 2.
It will be a single-center, prospective, observational study will be conducted, including consecutive patients hospitalized for myocardial infarction at the Montreal Heart Institute.
Every patient at the Cardiac Care Unit will undergo non-fasting lipid panel testing at day 0 of their admission for Myocardial Infarction during the study period. Patients who consent to participate will have a 2nd non-fasting lipid panel drawn at day 2 of their admission.
The proportion of patients who undergo a repeat lipid panel, and the proportion with a LDL, non-HDL, or apoB value above the intensification threshold, at 4-6 weeks post-discharge, will be assessed. There will be no contact with participants after discharge.
A sample size of 80 to100 patients is aimed for in this exploratory study, based on feasibility and convenience. This sample size is however likely to provide enough power for the primary objective of comparing LDL levels on day 0 and day 2.
Statistical analysis will be conducted at the two-sided 0.05 significance level and performed with SAS.
LDL levels at day 0 and at day 2 will be compared using a paired Student t-test. The changes in LDL from day 0 to day 2 will be estimated and presented with a 95% confidence interval. Results will also be graphically displayed in a bar graph.
1,073 studies on the registry are indexed under Dyslipidemias; 158 are open to participants now.
This study's planned enrollment of 100 is below the median of 600 across 204 observational studies indexed under Dyslipidemias.
Browse Dyslipidemias studies →Montreal Heart Institute is the lead sponsor of 101 studies on the registry; 25 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Adult patients hospitalized at the Cardiac Care Unit at the Montreal Heart Institute.
Exclusion Criteria:
Lipid panel measuring levels of LDL, non-HDL and apoB
Variation in LDL
Evaluation of the variation in LDL levels during a hospital admission for myocardial infarction
Time frame: Day 0 to day 2
Variation in non-HDL and apoB
Evaluation of the variation in non-HDL and apoB levels during a hospital admission for myocardial infarction
Time frame: Day 0 to day 2
Evaluation of intensification threshold
Among the subgroup of patients who are already treated with lipid-lowering therapy at the time of admission, the proportion of patients with a LDL, non-HDL or apoB value above the intensification threshold
Time frame: Day 0 to day 2
Repeat lipid panel after discharge
Evaluation of the proportion of patients discharged after myocardial infarction who undergo a repeat lipid panel after discharge
Time frame: 4-6 weeks
Evaluation of intensification threshold after discharge
Evaluation of the proportion of patients discharged after MI with a LDL, non-HDL or apoB value above the intensification threshold after discharge
Time frame: 4-6 weeks
Plan to share: Undecided
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Montreal Heart Institute